Foghorn therapeutics appoints ian smith to its board of directors

Cambridge, mass., april 28, 2021 (globe newswire) -- foghorn therapeutics inc. (nasdaq: fhtx), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of ian smith to its board of directors effective, april 27.

FHTX Ratings Summary

FHTX Quant Ranking